New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.
In vitro data have demonstrated a high amount of receptors for various hormones and peptides on malignant cells of neuroendocrine origin. Among these, binding sites for members of the SST-family (hSSTR1-5) are frequently found, and their expression has led to therapeutic and diagnostic attempts to specifically target these receptors. Receptor scintigraphy using radiolabeled peptide ligands has proven its effectiveness in clinical practice. In addition, initial results have indicated a clinical potential for receptor-targeted radiotherapy. Based on somatostatin (SST) receptor (R) recognition, the novel radiopharmaceuticals 111In/90Y-DOTA-lanreotide developed at the University of Vienna as well as 111In/90Y-DOTA-DPhe1-Tyr3-octreotide (NOVARTIS) both have provided promising data for diagnosis and treatment of hSSTR-positive tumors. SSTR scintigraphy using 111In-DTPA-DPhe1-octreotide has a high positive predictive value for the vast majority of neuroendocrine tumors and has gained its place in the diagnostic work-up as well as follow-up of patients. We have used 111In-DOTA-lanreotide scintigraphy in 166 patients since 1997 and have seen positive results in 93% of patients. In 42 patients with neuroendocrine tumors comparative data were obtained. As opposed to 111In-DTPA-DPhe1-octreotide and 111In-DOTA-DPhe1-Tyr3-octreotide, discrepancies in the scintigraphic results were seen in about one third of patients concerning both the tumor uptake as well as tumor lesion detection. Initial results both with 90Y-DOTA-lanreotide as well as 90Y-DOTA-DPhe1-Tyr3-octreotide has pointed out the clinical potential of radionuclide receptor-targeted radiotherapy. This new therapy could offer palliation and disease control at a reduced cost. The final peptide therapy strategy is most probably cheaper than conventional radiotherapies or prolonged chemotherapies. Overall, receptor-mediated radiotherapy with 90Y-DOTA-lanreotide/90Y-DOTA-DPhe1-Tyr3-octre otide might also be effective in patients refractory to conventional strategies.
Department of Nuclear Medicine, University of Vienna, Austria.
I
I
Virgolini
T
T
Traub
M
M
Leimer
C
C
Novotny
T
T
Pangerl
S
S
Ofluoglu
E
E
Halvadjieva
P
P
Smith-Jones
J
J
Flores
S R
SR
Li
P
P
Angelberger
E
E
Havlik
F
F
Andreae
M
M
Raderer
A
A
Kurtaran
B
B
Niederle
R
R
Dudczak
D006801:Humans; D007205:Indium Radioisotopes; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D015282:Octreotide; D010456:Peptides, Cyclic; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives; D015021:Yttrium Radioisotopes
D007205:Indium Radioisotopes; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide